Julie Lekstrom-Himes

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia

Haydar Frangoul, David Altshuler, Maria Domenica Cappellini et al. · New England Journal of Medicine · 2020 · 1.9K citations · Full text

Life Sciences, Genetics, Hematology +17

Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

Jennifer L. Taylor‐Cousar, À. Munck, Edward F. McKone et al. · New England Journal of Medicine · 2017 · 778 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis

Steven M. Rowe, Cori Daines, Felix C. Ringshausen et al. · New England Journal of Medicine · 2017 · 511 citations · Full text

Medicine, Genetics, Molecular Genetics +13

Enhancement of Hematopoietic Stem Cell Repopulating Capacity and Self-Renewal in the Absence of the Transcription Factor C/EBPα

Pu Zhang, Junko Iwasaki-Arai, Hiromi Iwasaki et al. · Immunity · 2004 · 498 citations · Full text

Life Sciences, Cell Biology, Hematology +12

Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein ɛ-deficient mice

Ryuya Yamanaka, Carrolee Barlow, Julie Lekstrom-Himes et al. · Proceedings of the National Academy of Sciences · 1997 · 386 citations

Life Sciences, Genetics, Immunology +15